Tryptophan depletion in chronic fatigue syndrome, a pilot cross-over study
Open Access
- 16 September 2014
- journal article
- research article
- Published by Springer Nature in BMC Research Notes
- Vol. 7 (1) , 650
Abstract
Chronic fatigue syndrome (CFS) is still an enigmatic disorder. CFS can be regarded as a complex disorder with tremendous impact on lives of CFS-patients. Full recovery without treatment is rare. A somatic explanation for the fatigue is lacking. There is clinical and experimental evidence implicating enhanced serotonergic neurotransmission in CFS. Genetic studies and imaging studies support the hypothesis of upregulated serotonin system in CFS. In line with the hypothesis of an increased serotonergic state in CFS, we performed a randomised clinical trial investigated the effect of 5-HT3 receptor antagonism in CFS. No benefit was found of the 5-HT3 receptor antagonist ondansetron compared to placebo. To further investigate the involvement of serotonin in CFS we performed a placebo controlled cross over pilot study investigating the effect of Acute Tryptophan Depletion. Five female CFS-patients who met the US Center for Disease Control and Prevention criteria for CFS were recruited. There were two test days, one week apart. Each participant received placebo and ATD. To evaluate the efficacy of the ATD procedure tryptophan and the large neutral amino acids were measured. The outcome measures were fatigue severity, concentration and mood states. ATD resulted in a significant plasma tryptophan to large neutral amino acid ratio reduction of 96%. There were no significant differences in fatigue-, depression and concentration between the placebo- and ATD condition. These first five CFS-patients did not respond to the ATD procedure. However, a much larger sample size is needed to draw final conclusions on the hypothesis of an increased serotonergic state in the pathophysiology of CFS. ISRCTN07518149Keywords
This publication has 22 references indexed in Scilit:
- The Effect of Ondansetron, a 5-HT3Receptor Antagonist, in Chronic Fatigue SyndromeThe Journal of Clinical Psychiatry, 2010
- Genetic evaluation of the serotonergic system in chronic fatigue syndromePsychoneuroendocrinology, 2008
- “How Fatigued Do You Currently Feel?” Convergent and Discriminant Validity of a Single‐Item Fatigue MeasureJournal of Occupational Health, 2007
- Acute Tryptophan Depletion. Part II: Clinical Effects and ImplicationsAustralian & New Zealand Journal of Psychiatry, 2005
- Acute Tryptophan Depletion. Part I: Rationale and MethodologyAustralian & New Zealand Journal of Psychiatry, 2005
- Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635Biological Psychiatry, 2005
- Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorderBiological Psychiatry, 2004
- Effects of Acute Tryptophan Depletion on Mood and Cortisol Release in First-degree Relatives of Type I and Type II Bipolar Patients and Healthy Matched ControlsNeuropsychopharmacology, 2002
- Validation of the determination of amino acids in plasma by high-performance liquid chromatography using automated pre-column derivatization with o-phthaldialdehydeJournal of Chromatography B: Biomedical Sciences and Applications, 1995
- Dimensional assessment of chronic fatigue syndromeJournal of Psychosomatic Research, 1994